MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Bioventus Revenue 2011-2026 | BVS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Bioventus
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 512 M | 512 M | 431 M | 321 M | 340 M | 319 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 512 M | 319 M | 406 M |
Quarterly Revenue Bioventus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 M | 148 M | 124 M | 139 M | 151 M | 129 M | 121 M | 137 M | 119 M | - | 129 M | 140 M | 117 M | - | 109 M | 110 M | 81.8 M | - | 85.9 M | 58 M | 78.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 151 M | 58 M | 118 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.03 | -2.26 % | $ 98.3 K |  USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 23.35 | -2.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.29 | -12.26 % | $ 1.64 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | - | - | $ 79.8 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 39.74 | 1.48 % | $ 1.1 B | USA |
 |
Danaher Corporation
DHR
|
23.9 B | $ 219.29 | -0.08 % | $ 160 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
3.62 B | $ 73.31 | -0.93 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 20.55 | -1.23 % | $ 1.1 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.76 B | $ 102.41 | 0.1 % | $ 19 B | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.2 | -0.97 % | $ 289 M | Israel |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 26.19 | -0.19 % | $ 792 M | USA |
 |
Guardant Health
GH
|
739 M | $ 113.17 | 2.43 % | $ 13.9 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
IDEXX Laboratories
IDXX
|
3.9 B | $ 672.84 | -0.57 % | $ 55.5 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
15.4 B | $ 230.33 | -2.19 % | $ 41.8 B | USA |
 |
Charles River Laboratories International
CRL
|
4.05 B | $ 210.51 | -0.59 % | $ 10.8 B | USA |
 |
Lantheus Holdings
LNTH
|
1.53 B | $ 66.91 | 0.34 % | $ 4.63 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 186.45 | 2.27 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
71.3 M | $ 10.11 | 4.66 % | $ 1.31 B | USA |
 |
Precipio
PRPO
|
15.2 M | $ 24.07 | -0.78 % | $ 31.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
13 B | $ 271.34 | 0.56 % | $ 22.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 181.44 | -2.39 % | $ 15 B |  Irlanda |
 |
Medpace Holdings
MEDP
|
2.11 B | $ 582.66 | -1.76 % | $ 18 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
18 B | $ 28.66 | -2.02 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
6.32 B | $ 133.33 | 0.07 % | $ 40.5 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.41 | 0.84 % | $ 5.54 M | USA |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 27.24 | -0.62 % | $ 1.15 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |